Sino Biological, Inc. (Shenzhen Stock Exchange: 301047.SZ), a global leader in recombinant technology, is proud to announce the launch of its innovative XPressMAX™ Cell-Free Protein Synthesis Kit (Cat#: CFKIT02), a cutting-edge solution designed to supercharge artificial intelligence (AI)-driven high-throughput screening pipelines for antibody drug discovery.
XPressMAX™ Cell-Free Protein Synthesis Kit
The novel kit leverages advanced cell-free protein synthesis technology to enable rapid, efficient in vitro production of target proteins and antibodies—eliminating the constraints of traditional cell-based expression systems. By seamlessly integrating with AI-powered screening platforms, the new offering empowers researchers to dramatically accelerate the identification and optimization of promising antibody candidates, reducing both development timelines and costs.
Based on an E. coli lysate and fully supplemented with essential transcription and translation components, XPressMAX™ enables direct protein synthesis from plasmid or PCR templates. Specifically designed for antibody drug discovery, XPressMAX™ enables rapid expression and validation of VHH, scFv, Fab, and Miniprotein. Leveraging XPressMAX™, Sino Biological has established a high-throughput cell-free expression platform that validates 2,000+ scFv/VHH molecules in 3–4 weeks to match AI’s rapid iteration.
